In April 2019 the India National Anti-Doping Agency (INADA) has reported an anti-doping rule violation against the badminton Parathlete Sankar S. after his sample tested positive for the prohibited substances 19-norandrosterone and 19-noretiocholanolone (Nandrolone). After notification a provisional suspension was ordered and the Athlete was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).
The Athlete accepted the test result and denied the intentional use of the substances. He explained with medical evidence that for his back pain he underwent treatment in a hospital where his doctor had administered him with prescribed Deca Durabolin (Nandrolon). He mentioned this medication on the Doping Control Form and thereupon he applied for a retroactive TUE which was denied in September 2021.
INADA contended that the Athlete had acted negligently as he failed to mention to his doctor that he is an Athlete. He didn't check his medication before using and the treatment with this product is not appropriate for this condition.
The Panel finds that the presence of the prohibited subtances has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation. The Panel accepts that the violation was not intentional and considers that he acted with some degree of fault or negligence.
Therefore the ADDP decides on 18 April 2022 to impose a 2 year period of ineligibility on the Parathlete, starting on the date of the provisional suspension.
